ATA Guidelines Tools

Anaplastic Thyroid Cancer ATA 2021

American Thyroid Association Quick-Reference GUIDELINES Apps

Issue link: https://eguideline.guidelinecentral.com/i/1441026

Contents of this Issue

Navigation

Page 18 of 27

19 Definitive intention radiation (IMRT) +/– Chemotherapy (taxane monotherapy or with platin or anthracycline) Palliative Chemotherapy and/or Radiation Best Supportive Care/Hospice Surgery (if feasible) N Y Targeted therapy (e.g., fusions, ALK: crizotinib, ceritinib, alectinib; RET: pralsetinib, selpercatinib; NTRK: larotrectinib, entrectinib) 1 or or Excellent tumor response? 1 Additional agents exist and are in development, listing not meant to be comprehensive; clinical trials preferred if available; see text.

Articles in this issue

Archives of this issue

view archives of ATA Guidelines Tools - Anaplastic Thyroid Cancer ATA 2021